Silverarc Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Silverarc Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-150,000	Closed	-$8.81M	–	100
2023 Q4	$8.81M	Hold	150,000	–	–	2.62%	12
2023 Q3	$6.53M	Hold	150,000	–	–	1.98%	18
2023 Q2	$5.42M	Buy	+150,000	New	+$6.18M	1.68%	19
2022 Q4	–	Sell	-42,500	Closed	-$2.97M	–	104
2022 Q3	$2.97M	Sell	42,500 -58,400	-58%	-$4.32M	1%	32
2022 Q2	$6.77M	Buy	+100,900	New	+$6.42M	2.09%	18

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Silverarc Capital Management's MRTX Position: Q4 2023 in Review

Silverarc Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 200,000 shares — an estimated $11.2M sold.

Silverarc Capital Management first reported a position in MRTX in Q4 2020 and held it in 10 quarters. The position peaked at $8.91M in Q4 2021. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

Silverarc Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Silverarc Capital Management sold 200,000 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $11.2M.
Silverarc Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 10 quarters.
Silverarc Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $8.91M in Q4 2021.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Silverarc Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.